In a study involving 11,605 women, Marvelon was shown to reduce the incidence of spotting and breakthrough bleeding (BTB) - after an initial increase - to levels below pre-treatment after 5 cycles.

• 一项包括11605位妇女的研究；妈富隆可减少点滴出血和突破性出血率-最初可能表现为增加；3-6个周期后可降至低于使用前的水平.